查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1801872

血漿分餾市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Plasma Fractionation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球血漿分離市場規模達337億美元，預計2034年將以6.6%的複合年成長率成長，達到653億美元。這項市場擴張的驅動力在於：免疫球蛋白在各種治療方案中的應用日益廣泛，對高階醫療保健方案的需求日益成長，以及分離技術的持續改進。確診患有遺傳和免疫疾病的患者數量顯著增加，推動了血漿衍生療法的普及。隨著診斷技術的進步，慢性疾病的可近性不斷提升，患者獲得血漿蛋白治療的機會也日益增加。血漿分離，即從捐捐血液中提取和分離關鍵蛋白質的工業工藝，正是這項變革的核心。

血漿分餾市場 - IMG1

血漿蛋白（例如白蛋白和凝血因子）在多種疾病的治療中至關重要。自體免疫疾病和遺傳性疾病的發生率不斷上升，促使這些療法的應用範圍不斷擴大。研發投入的增加進一步推動了不同醫療保健領域血漿療法的創新。從管理免疫缺陷到治療出血性疾病，血漿成分的應用範圍正在顯著擴大，有助於在預測期內保持穩定的需求。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 337億美元
預測值 653億美元
複合年成長率 6.6%

2024年，免疫球蛋白細分市場佔據46.8%的市場佔有率，反映出對用於治療各種健康狀況的血漿療法的強勁需求。受免疫和神經系統疾病患者數量的增加所推動，該細分市場的使用量正在激增。靜脈注射免疫球蛋白（IVIg）在臨床環境中的超說明書應用日益增多，以及其在治療格林-巴利綜合症和川崎病等疾病方面的廣泛應用，鞏固了其在市場上的主導地位，並支持了其持續成長。

2024年，冷乙醇分餾技術佔47.9%的市佔率。由於其高效、經濟且能夠生產高純度血漿蛋白，該技術仍然是大型血漿處理設施的標準。它適用於同時提取多種蛋白質，並兼具安全性和提取性能。其在分離關鍵血漿成分（例如免疫球蛋白和白蛋白）方面應用尤為廣泛。

2024年，美國血漿分離市場規模達104億美元。憑藉強大的醫療基礎設施、血漿療法的認知度以及廣泛的捐贈中心，美國在該領域保持領先地位。慢性病盛行率的上升以及免疫球蛋白和凝血因子在臨床治療中的常規使用，擴大了對血漿衍生產品的需求。隨著越來越多的患者需要長期治療，對可靠血漿蛋白供應的需求持續攀升，從而增強了美國市場的實力。

活躍於血漿分離市場的主要公司包括武田製藥、Kedrion Biopharma、Grifols、Prothya Biosolutions、GC Biopharma、SK Plasma、Kamada Pharmaceuticals、LFB Group、VIRCHOW BIOTECH PRIVATE LIMITED、日本血液製品組織 (JB)、Intas Pharmaceticals、TECH PRIVATE LIMITED、日本血液製品組織 (JB)、Intas Pharmaceuticals、Intas Pharmauticals、Octibu Group。為了在全球血漿分離市場站穩腳跟，領先的公司正在實施以產能擴張、策略合作和加工方法創新為重點的策略。他們正在加大研發投入，探索血漿衍生蛋白的新型治療應用。許多公司也與醫療保健提供者和政府機構簽訂了長期協議，以確保穩定的供需。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 對先進治療方案的需求不斷成長
      • 免疫球蛋白在各種治療應用的應用日益增多
      • 呼吸系統疾病和遺傳疾病的盛行率不斷上升
      • 血漿分離技術進步
    • 產業陷阱與挑戰
      • 嚴格的監理政策
      • 替代方案的出現
    • 市場機會
      • 政府有利於自給自足的策略
      • 血漿衍生療法的研發活動日益增多
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 技術進步
    • 當前的技術趨勢
    • 新興技術
  • 血漿分離過程概述
  • 價值鏈分析
  • 2024年各地區白蛋白銷量
  • 市場演變與歷史背景
  • 波特的分析
  • PESTEL分析
  • 未來市場趨勢
  • 差距分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • MEA
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係和合作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

  • 主要趨勢
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下免疫球蛋白
    • 其他免疫球蛋白
  • 凝血因子
    • 第八因子
    • 凝血因子IX
    • 凝血酶原複合物濃縮物
    • 血管性血友病因子
    • 纖維蛋白原濃縮物
    • 其他凝血因子濃縮物
  • 白蛋白
  • 蛋白酶抑制劑
  • 其他血漿產品

第6章：市場估計與預測：依方法，2021 - 2034 年

  • 主要趨勢
  • 冷乙醇分餾
  • 色譜法
  • 離心
  • 其他方法

第7章：市場估計與預測：按應用，2021 - 2034 年

  • 主要趨勢
  • 免疫學
  • 神經病學
  • 血液學
  • 肺部疾病學
  • 腫瘤學
  • 其他應用

第8章：市場估計與預測：依最終用途，2021 - 2034 年

  • 主要趨勢
  • 醫院和診所
  • 臨床研究實驗室
  • 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • LFB Group
  • CSL
  • GC Biopharma
  • Grifols
  • Intas Pharmaceuticals
  • Japan Blood Products Organization (JB)
  • Kamada Pharmaceuticals
  • Kedrion Biopharma
  • Octapharma
  • Prothya Biosolutions
  • SK Plasma
  • Taibang Biologic Group
  • Takeda
  • VIRCHOW BIOTECH PRIVATE LIMITED
簡介目錄
Product Code: 14588

The Global Plasma Fractionation Market was valued at USD 33.7 billion in 2024 and is estimated to grow at a CAGR of 6.6% to reach USD 65.3 billion by 2034. This market expansion is being shaped by the increasing usage of immunoglobulins across a range of therapeutic treatments, higher demand for sophisticated healthcare options, and continuous improvements in fractionation technologies. A significant rise in the number of patients diagnosed with genetic and immunological conditions is pushing the adoption of plasma-derived therapies. With chronic illnesses becoming more detectable through improved diagnostics, patient access to treatments requiring plasma proteins is increasing. Plasma fractionation, the industrial process used to extract and isolate critical proteins from donated blood, is at the center of this transformation.

Plasma Fractionation Market - IMG1

Plasma proteins such as albumin and coagulation factors are essential in the treatment of multiple disorders. The growing frequency of autoimmune and inherited diseases is contributing to the broader use of these therapies. Increased R&D investments are further driving innovations in plasma-based treatments across diverse healthcare segments. From managing immune deficiencies to treating bleeding disorders, the applications of fractionated plasma components are expanding significantly, helping to fuel consistent demand through the forecast period.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$33.7 Billion
Forecast Value$65.3 Billion
CAGR6.6%

The immunoglobulins segment accounted for a 46.8% share in 2024, reflecting strong demand for plasma-based therapies used in treating a broad range of health conditions. The segment is witnessing a surge in usage driven by a growing number of immunological and neurological diseases. Increasing off-label application of IVIg in clinical settings and its wider adoption for managing conditions like Guillain-Barre syndrome and Kawasaki disease are contributing to its dominant position in the market and supporting sustained growth.

The cold ethanol fractionation segment held a 47.9% share in 2024. The technique remains a standard in large-scale plasma processing facilities due to its efficiency, cost-effectiveness, and ability to yield high-purity plasma proteins. It is favored for extracting multiple protein types simultaneously and offers an optimal mix of safety and extraction performance. Its use is especially widespread for isolating key plasma components such as immunoglobulins and albumin.

U.S. Plasma Fractionation Market was valued at USD 10.4 billion in 2024. The country maintains a leadership position in this sector due to strong healthcare infrastructure, high awareness of plasma-based therapies, and widespread availability of donation centers. Increasing prevalence of chronic conditions and the routine use of immunoglobulins and coagulation factors in clinical care have amplified the demand for plasma-derived products. As more patients require long-term therapies, the need for reliable plasma protein supply continues to climb, bolstering U.S. market strength.

Key companies active in the Plasma Fractionation Market include Takeda, Kedrion Biopharma, Grifols, Prothya Biosolutions, GC Biopharma, SK Plasma, Kamada Pharmaceuticals, LFB Group, VIRCHOW BIOTECH PRIVATE LIMITED, Japan Blood Products Organization (JB), Intas Pharmaceuticals, Octapharma, CSL, and Taibang Biologic Group. To secure a strong foothold in the Global Plasma Fractionation Market, leading companies are implementing strategies focused on capacity expansion, strategic collaborations, and innovation in processing methods. They are increasing investments in research and development to explore new therapeutic applications of plasma-derived proteins. Many firms are also forming long-term agreements with healthcare providers and government agencies to ensure consistent demand and supply.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Method trends
    • 2.2.4 Application trends
    • 2.2.5 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for advanced treatment options
      • 3.2.1.2 Rising adoption of immunoglobulins in various therapeutic applications
      • 3.2.1.3 Increasing prevalence of respiratory and genetic disorders
      • 3.2.1.4 Technological advancements in plasma fractionation
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Emergence of alternative options
    • 3.2.3 Market opportunities
      • 3.2.3.1 Favourable government strategies for self-sufficiency
      • 3.2.3.2 Growing research and development activities for plasma-derived therapies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Plasma fractionation process overview
  • 3.7 Value chain analysis
  • 3.8 Albumin unit sales by region, 2024
  • 3.9 Market evolution and historical context
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis
  • 3.12 Future market trends
  • 3.13 Gap analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Asia Pacific
    • 4.2.5 Latin America
    • 4.2.6 MEA
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Immunoglobulins
    • 5.2.1 Intravenous immunoglobulins
    • 5.2.2 Subcutaneous immunoglobulins
    • 5.2.3 Other immunoglobulins
  • 5.3 Coagulation factors
    • 5.3.1 Factor VIII
    • 5.3.2 Factor IX
    • 5.3.3 Prothrombin complex concentrates
    • 5.3.4 VON WILLEBRAND factor
    • 5.3.5 Fibrinogen concentrates
    • 5.3.6 Other coagulation factor concentrates
  • 5.4 Albumin
  • 5.5 Protease inhibitors
  • 5.6 Other plasma products

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Cold ethanol fractionation
  • 6.3 Chromatography
  • 6.4 Centrifugation
  • 6.5 Other methods

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Immunology
  • 7.3 Neurology
  • 7.4 Hematology
  • 7.5 Pulmonology
  • 7.6 Oncology
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Clinical research laboratories
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 LFB Group
  • 10.2 CSL
  • 10.3 GC Biopharma
  • 10.4 Grifols
  • 10.5 Intas Pharmaceuticals
  • 10.6 Japan Blood Products Organization (JB)
  • 10.7 Kamada Pharmaceuticals
  • 10.8 Kedrion Biopharma
  • 10.9 Octapharma
  • 10.10 Prothya Biosolutions
  • 10.11 SK Plasma
  • 10.12 Taibang Biologic Group
  • 10.13 Takeda
  • 10.14 VIRCHOW BIOTECH PRIVATE LIMITED